Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Recipe For Doubling Innovative Medicines Includes New Approval Pathway, FDA Management Changes

Executive Summary

Presidential advisory panel makes eight recommendations to improve innovation in drug discovery, development and evaluation; calls for broad partnership of stakeholders to accelerate therapeutics, $40 million annual appropriations for FDA’s Sentinel System.

Advertisement

Related Content

Antibiotic Development To Get Fresh Push, Not Fresh Ideas, From PCAST
FDA, Uninvited To Congress’ PCAST Hearing, Blogs Its Accomplishments
Lagging CDER Review Divisions Could Learn From Oncology, Antiviral Offices
Biomedical Innovation Meeting From Energy and Commerce Shows Possible Legislative Roadmap
Not So Fast On Expedited Approvals, Drug Safety Researchers Caution
Not So Fast On Expedited Approvals, Drug Safety Researchers Caution
PDUFA V: Accelerated Approval Expansion May Outshine Rare Disease Improvements
Antibiotic Incentives: FDA’s Woodcock Says LPAD Could Be Better Than Exclusivity, But Questions Remain
FDA Exploring Limited-Use Approvals For Antibiotics Based On Small Development Programs
BIO Wants Expanded Accelerated Approval In PDUFA Instead Of Progressive Approval

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054784

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel